Positive results announced with first in-human study of tigilanol tiglate in solid tumours
13 November 2018
QBiotics Group Ltd has received positive results from the first in-human Phase I/IIA clinical trial of its anticancer pharmaceutical tigilanol tiglate in patients with solid tumours. The study was conducted across four Australian hospitals.
The first in-human Phase I/IIA clinical trial evaluated the dose-escalation, preliminary efficacy, and pharmacokinetics of intratumoural tigilanol tiglate in patients with cutaneous, subcutaneous, head and neck or nodal tumours.
Results from the safety and tolerability study indicated intratumoural tigilanol tiglate was well tolerated, as a Maximum Tolerated Dose for the drug was not reached, and signs of clinical efficacy were identified in nine different tumour types including Complete Response (full tumour destruction) achieved in 2 patients. These positive results support QBiotics’ plans for a Clinical Phase IIA efficacy trial.